| 翻訳と辞書 |
PRO 140
PRO 140 is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of HIV infection. The United States Food and Drug Administration has designated PRO 140 for fast-track approval.〔Brian Lawler. (''Progenics' Intriguing Study Results'' ). The Motley Fool. 2 May 2007.〕 In February 2008, the drug entered Phase 2 clinical trials and a phase 3 trial was begun in 2015.
==Development==
PRO 140 is being developed by Cytodyn Inc. In May 2007, results from the phase I clinical trial of the drug demonstrated "potent, rapid, prolonged, dose-dependent, highly significant antiviral activity" for PRO 140. Participants in the highest-dosing group received 5 milligrams per kilogram and showed an average viral load decrease of -1.83 log10. On average, reductions of greater than -1 log10 per millilitre were maintained for between two and three weeks, from only a single dose of the drug.〔Derek Thaczuk. (''ICAAC: Phase 1 study provides 'proof of concept' for PRO 140, a monoclonal CCR5 antibody'' ). AIDSmap.com. 21 Sept 2007.〕 The largest individual HIV RNA reductions ranged up to -2.5 log10 among patients receiving both the 2 and 5 mg/kg doses.〔Liz Highleyman. (''Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study'' ). 28 Sept 2007. HIVandHepatitis.com〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「PRO 140」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|